Compare SNPS & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNPS | GSK |
|---|---|---|
| Founded | 1986 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.0B | 95.3B |
| IPO Year | 1992 | N/A |
| Metric | SNPS | GSK |
|---|---|---|
| Price | $470.60 | $49.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $566.13 | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 3.0M |
| Earning Date | 12-10-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.38% |
| EPS Growth | N/A | ★ 118.57 |
| EPS | ★ 8.05 | 1.79 |
| Revenue | $7,054,178,000.00 | ★ $43,237,357,842.00 |
| Revenue This Year | $39.24 | $6.70 |
| Revenue Next Year | $10.82 | $5.10 |
| P/E Ratio | $58.21 | ★ $13.34 |
| Revenue Growth | ★ 15.12 | 2.73 |
| 52 Week Low | $365.74 | $31.72 |
| 52 Week High | $651.73 | $49.44 |
| Indicator | SNPS | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 58.71 |
| Support Level | $472.00 | $48.69 |
| Resistance Level | $484.60 | $49.40 |
| Average True Range (ATR) | 12.72 | 0.48 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 57.17 | 72.50 |
Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.